Teva

Executive Summary

Teva Pharmaceutical Industries Ltd. operates as a global leader in generics and biosimilars while expanding its innovative medicines portfolio, primarily in neuroscience and immunology. With a dual business model, the company benefits from a broad generic drug portfolio that generates stable cash flows, offset by pricing pressures and debt reduction efforts. Recent focus has been on high-value biosimilars and specialty drugs like Austedo and Ajovy, which have contributed to revenue growth and margin improvement. The company’s pipeline includes several late-stage biosimilars targeting major biologic drugs, as well as novel candidates in CNS and immunology, positioning Teva for long-term value creation despite challenges in the generic market. Overall, Teva remains a key player in global pharmaceuticals, with its diversified platform and strategic initiatives supporting a gradual turnaround.

Upcoming Catalysts (preview)

• Q4 2025FDA Decision on Biosimilar to Stelara (Ustekinumab)80% success
• Q3 2025Launch of Generic Entresto (Sacubitril/Valsartan)90% success
• H1 2026Phase 3 Data Readout for TEV-48574 (Depression / CNS)60% success